Venn Expands in Europe with Two Acquisitions
News Dec 10, 2013
Venn Life Sciences has announced the recent acquisition of two European Clinical Research Organizations. Venn acquired German CRO CRM clinical trials and Medevol Clinical Services in the UK.
Founded in 1996, CRM is a full-service CRO based in Rheinbach, Germany, specializing in Phases II-IV. In addition to extensive experience in dermatology, pneumology and urology, the CRM team have considerable expertise in conducting clinical trials in the field of sports medicine, as well as in the running of non-interventional studies.
CRM also serves the Austrian and Italian regions and gives the combined organization a ready-made and robust base of business with an expanded group of regular clients from some of the world’s leading pharmaceutical, biotechnology and medical devices companies.
CRM’s suite of services include initial and ongoing training for study nurses, investigators and trial teams in the areas of quality, planning and monitoring of clinical studies. The company has worked closely with Government agencies to ensure that the courses they undertake, particularly for Study Nurses, provide a full understanding of protocols and protects the rights, safety and well-being of the trial subjects, which then assures the credibility of the clinical trial data generated.
Medevol has been an active CRO in the UK clinical trials market since 2001, conducting full-service studies for global pharmaceutical and biotechnology companies across Phases II - IV.
With extensive therapeutic experience across a broad range of indications, Medevol also provide contract staffing solutions, offering companies the flexibility to manage different levels of resourcing needs throughout the clinical trial process.
Based in Belfast, Medevol complements Venn’s UK clinical operations with their valued history and investigator contacts throughout the UK.
These two additions to Venn’s European operations bring a common leading global client with ongoing and future projects booked. Venn can now offer its clients enhanced services and experience in the management, resourcing and conducting of clinical trials in Europe.
Commenting on the acquisitions, Tony Richardson, CEO of Venn, said: “The addition of these two offices to Venn’s European operations further aligns our actions to our overall strategy of becoming a leading mid-sized European CRO. The skills and talent that we are adding to our company enhance our reputation as a CRO that stays close to its clients, guiding them through the often complicated process of conducting trials across Europe. We as a company are also looking at adding to these acquisitions over the coming months and increasing our office locations across Europe.”
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE